Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome
Metrics: PDF 829 views | HTML 2503 views | ?
Aida Kiviniemi1,2, Maria Gardberg3, Katri Kivinen4, Jussi P. Posti5, Ville Vuorinen5, Jussi Sipilä6,7, Melissa Rahi5, Matti Sankinen5 and Heikki Minn8
1Department of Radiology, Medical Imaging Center of Southwest Finland, Turku University Hospital and University of Turku, Turku, Finland
2Turku PET Center, Turku University Hospital and University of Turku, Turku, Finland
3Department of Pathology, Turku University Hospital and University of Turku, Turku, Finland
4TYKSLAB, Laboratory of Molecular Genetics, Turku University Hospital, Turku, Finland
5Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, Turku, Finland
6Department of Neurology, North Karelia Central Hospital, Joensuu, Finland
7Division of Clinical Neurosciences, Department of Neurology, Turku University Hospital and University of Turku, Turku, Finland
8Department of Oncology and Radiotherapy, Turku University Hospital, Turku, Finland
Aida Kiviniemi, email: email@example.com
Keywords: glioma, somatostatin receptor, oligodendroglioma, IDH mutation, prognosis
Received: February 20, 2017 Accepted: April 03, 2017 Published: April 13, 2017
Somatostatin receptor subtype 2A (SSTR2A) is a potential therapeutic target in gliomas. Data on SSTR2A expression in different glioma entities, however, is particularly conflicting. Our objective was to characterize SSTR2A status and explore its impact on survival in gliomas classified according to the specific molecular signatures of the updated WHO classification. In total, 184 glioma samples were retrospectively analyzed for SSTR2A expression using immunohistochemistry with monoclonal antibody UMB-1. Double staining with CD68 was used to exclude microglia and macrophages from analyses. SSTR2A staining intensity and its localization in tumor cells was evaluated and correlated with glioma entities and survival. Diagnoses included 101 glioblastomas (93 isocitrate dehydrogenase (IDH) -wildtype, 3 IDH-mutant, 5 not otherwise specified (NOS)), 60 astrocytomas (22 IDH-wildtype, 37 IDH-mutant, 1 NOS), and 23 oligodendrogliomas (19 IDH-mutant and 1p/19q-codeleted, 4 NOS). SSTR2A expression significantly associated with oligodendrogliomas (79% SSTR2A positive) compared to IDH-mutant or IDH-wildtype astrocytomas (27% and 23% SSTR2A positive, respectively), and especially glioblastomas of which only 13% were SSTR2A positive (p < 0.001, Fisher’s exact test). The staining pattern in glioblastomas was patchy whereas more homogeneous membranous and cytoplasmic staining was detected in oligodendrogliomas. Positive SSTR2A was related to longer overall survival in grade II and III gliomas (HR 2.7, CI 1.2–5.8, p = 0.013). In conclusion, SSTR2A expression is infrequent in astrocytomas and negative in the majority of glioblastomas where it is of no prognostic significance. In contrast, oligodendrogliomas show intense membranous and cytoplasmic SSTR2A expression, which carries potential diagnostic, prognostic, and therapeutic value.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.